---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-011123"
form_type: "8-K"
ticker: null
cik: "0000849636"
company_name: "RespireRx Pharmaceuticals Inc."
filed_at: "2023-04-06T23:59:59+00:00"
generated_at: "2026-06-17T05:31:37.573371+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# RespireRx raises $25,000 via sale of 250 shares of Series I 8% Redeemable Preferred Stock

## Summary
- Raised $25,000 from two accredited investors for 250 shares of Series I 8% Redeemable Preferred Stock.
- Series I Preferred Stock carries 8% annual dividend payable in shares; redeemable upon events like license payments ≥$15M.
- Preferred stock is not convertible into common stock; transfer restricted except to family or affiliates.
- As of April 4, 2023, common shares outstanding: 144,326,672.
- Issuance exempt from registration under Section 4(a)(2) of the Securities Act.

## SEC filing metadata
- accession: 0001493152-23-011123
- form_type: 8-K
- cik: 0000849636
- company_name: RespireRx Pharmaceuticals Inc.
- filed_at: 2023-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/849636/000149315223011123/0001493152-23-011123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/849636/000149315223011123/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-011123
- JSON: https://secwatch.observer/filing/0001493152-23-011123.json
- Plain text: https://secwatch.observer/filing/0001493152-23-011123.txt

## Key facts
- Governance Changes
  RespireRx Pharmaceuticals Inc.: Filed Certificate of Designation for Series I Preferred Stock to amend the certificate of incorporation, setting forth preferences, rights and limitations of the new series (effective 2023-04-03).
  - Change: charter amendment
  - Effective: 2023-04-03
  source text: On April 3, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of its Series I Preferred Stock, also referred to herein as the “Certificate” with the Secretary of State of the State of Delaware to amend the Company’s certificate of incorporation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/849636/000149315223011123/0001493152-23-011123-index.htm
- Material Agreements
  RespireRx Pharmaceuticals Inc. entered into Securities Purchase Agreement with two individual accredited investors investing jointly valued at $25,000.00 (effective 2023-04-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: two individual accredited investors investing jointly
  - Value: $25,000.00
  - Effective: 2023-04-05
  source text: On April 5, 2023, RespireRx Pharmaceuticals Inc. (the “Company” or the “Corporation”) entered into a securities purchase agreement (“Securities Purchase Agreement) with two individual accredited investors investing jointly (“Investors”). Pursuant to the terms of the Securities Purchase Agreement, the investors invested $25,000.00 for 250 shares of Series I 8% Redeemable Preferred Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/849636/000149315223011123/0001493152-23-011123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.